Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. [electronic resource]
Producer: 20010531Description: 1605-11 p. digitalISSN:- 0149-5992
- Adult
- Aged
- Blood Glucose -- drug effects
- C-Peptide -- blood
- Diabetes Mellitus, Type 2 -- blood
- Dose-Response Relationship, Drug
- Double-Blind Method
- Ethnicity
- Female
- Glycated Hemoglobin -- analysis
- Humans
- Hypoglycemic Agents -- therapeutic use
- Male
- Middle Aged
- Pioglitazone
- Placebos
- Racial Groups
- Thiazoles -- therapeutic use
- Thiazolidinediones
- United States
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.